Context: Proprotein convertase subtilisin kexin 9 (PCSK9) mediates degradation of the low-density lipoprotein receptor (LDLR), thereby increasing plasma low-density lipoprotein cholesterol (LDL-C). Variations in the PCSK9 gene associated with loss of function (LOF) of PCSK9 result in greater expression of hepatic LDLR, lower concentrations of LDL-C, and protection from cardiovascular disease (CVD). Apolipoprotein-B (apoB) remnants also contribute to CVD risk and are similarly cleared by the LDLR. We hypothesized that PCSK9-LOF carriers would have lower fasting and postprandial remnant lipoproteins on top of lower LDL-C.
Conclusions: Participants carrying PCSK9-LOF variants had attenuated levels of fasting and postprandial TG, apoB48, and total apoB. This may confer protection from CVD and further validate the use of PCSK9 inhibitors to lower CVD risk. (J Clin Endocrinol Metab 102: 3452-3460, 2017) P roprotein convertase subtilisin kexin 9 (PCSK9) is a secreted protein expressed primarily in the liver and small intestine (1) . It is the ninth member of the family of proprotein convertases (2) . Unlike other proprotein convertases, it has only itself as substrate, and it escorts the low-density lipoprotein receptor (LDLR) to the lysosome for degradation (3) . By reducing the amount of cell surface LDLR, the low-density lipoprotein cholesterol (LDL-C) concentration is increased (4) . Consequently, PCSK9 inhibitors have been rapidly developed and are currently in clinical use. One of them, evolocumab, has recently been shown to further reduce the risk for cardiovascular events in patients who are already receiving statin therapy (5) .
The gene for PCSK9 is highly polymorphic (6) . Populations have variants that result in a more functional or increase in circulating PCSK9 [gain of function (GOF)] or, conversely, a less functional or decrease in circulating PCSK9 [loss of function (LOF)] (7). LOF variants are more common than GOF variants. PCSK9-LOF results in greater expression of hepatic LDLR, lower concentrations of LDL-C, and protection from cardiovascular disease (CVD) (8, 9) . LDL-C is a well-established risk marker of CVD and is used to assess and manage CVD risk (10) . Despite lowering LDL-C to recommended levels by statin therapy, there is substantial residual risk for cardiovascular events, especially in high-risk patients with diabetes and the metabolic syndrome (11) .
Recent data indicate that triglyceride (TG)-rich lipoproteins (TRLs) have a substantial and independent causal association with CVD risk (12) . Remnants of chylomicrons (CMs) and very-low-density lipoproteins (VLDLs) contain more cholesterol per particle than LDL and therefore have enhanced atherogenic potential (13) . Remnant lipoproteins in plasma are assessed by measuring fasting plasma apolipoprotein-B (apoB) 48 and apoB100, the functional proteins present on each CM and VLDL remnant particle, respectively (14) . The clearance of remnant lipoproteins is mediated by the liver through the LDLR and the LDLRrelated protein 1 (LRP1) (15) . Remnant lipoproteins bind to the LDLR through apolipoprotein-E (apoE)-related mechanisms (15) , whereas LDL binds through interactions with apoB100 (16) . Delayed clearance of TRL, especially in the postprandial period, results in accumulation of remnant lipoproteins in plasma, manifesting as hypertriglyceridemia and enhanced postprandial lipemia (PPL) (17, 18) .
PCSK9 could influence TRL clearance by reducing the amount of cell surface LDLR. In vitro, PCSK9 has also been shown to stimulate the production of TRL (19) . PCSK9 null mice have reduced postprandial TGs excursion as well as intestinal apoB48 expression following an olive oil bolus (20) . Collectively, the evidence presented suggests that PCSK9 could modulate both intestinal secretion and hepatic clearance of TRL. It is unknown whether PCSK9 affects TRL metabolism in humans, particularly during the postprandial period. We hypothesized that persons with PCSK9-LOF variants will have not only lower fasting LDL-C but also lower fasting and postprandial remnant lipoproteins. The aim of the current study was to compare the fasting and postprandial concentrations of TG, total apoB (as a surrogate of apoB100), and apoB48 as indicators of remnant lipoprotein metabolism in PCSK9-LOF carriers.
Materials and Methods

Population and study participants
Participants were recruited from a previously identified white and African Canadian pool (the Ottawa PCSK9 Cohort) that underwent full exonic sequencing of the PCSK9 gene (21) . Of this cohort, participants with one or more copies of the PCSK9 L10ins/A53V and/or I474V and/or R46L variants (n = 22) and no PCSK9 variants at all (n = 23) were identified and approached. Men and women aged 30 to 80 years with a body mass index (BMI) of 20 to 40 kg/m 2 , a fasting serum LDL-C level . 2.0 and ,7 mmol/L, a total cholesterol (TC)/highdensity lipoprotein cholesterol (HDL-C) ratio . 4.0, a TG level , 4.5 mmol/L, and an HDL-C level . 0.6 mmol/L were eligible.
Exclusion criteria included cognitive impairment, receipt of any medication for dyslipidemia for 6 weeks before the oral fat tolerance test (OFTT) or unknown supplements, nutraceuticals, herbal medications, and sex hormone therapy (including oral contraceptive pills or testosterone therapy), active or chronic hepatic or renal disease, presence of tendon xanthomas, type 1 or type 2 diabetes mellitus, untreated hypo-or hyperthyroidism, major illness (such as cancer and pulmonary and gastrointestinal disorders), acute illness or surgical procedure within the previous 3 months, alcohol consumption . 2 drinks per day (1 drink defined as 12 fl. oz of beer or 5 fl. oz of wine or 1.5 oz. of liquor), and apoE2/2, 3/2, 4/2 genotype to avoid the apoE2 allele (which is known to enhance PPL).
The 22 PCSK9-LOF variant participants had the following variants: I474V (9), L10ins/A53V (4), R46L (2), L10ins/A53V and I474V (3), L10ins/A53V and R46L (1) , and homozygous I474V (3) .
Study design
The current study was a case-control, metabolic study. The Research Ethics Board of the Ottawa Hospital Research Institute approved the study protocol. The study was conducted in the Clinical Research Center of the Ottawa Hospital. The OFTT was conducted by experienced staff in a dynamic function testing facility within the Clinical Research Center. Samples were processed, stored at 280°C, and subsequently analyzed in an adjoining clinical research laboratory and in Edmonton, Alberta. Participants from our previous study pool were invited to attend an interview. Those who agreed to participate provided written informed consent and underwent further history taking, examination, and laboratory screening to establish their eligibility. Tests done included serum glucose, creatinine, alanine aminotransferase, thyroid-stimulating hormone, apoE genotyping, and serum lipids, including total cholesterol, TG, HDL-C, LDL-C, and TC/HDL-C ratio. These results were used to determine eligibility for the OFTT.
Postprandial study (OFTT)
Eligible participants received dietary counseling from a certified dietitian and underwent a 6-week run-in dietary period to standardize the background diet. Participants were advised to refrain from physical exercise for 60 hours and abstain from alcohol for 36 hours before the OFTT because these are known to acutely affect PPL. A fat load was given at 08:00 hours after a 12-hour fast. The test drink consisted of 350 mL of whipping cream (35% fat), 2 tablespoons of chocolate-flavored syrup, 1 tablespoon of granulated sugar, and 1 tablespoon of instant nonfat dry milk. Of the total 880 kcal, 5.0% were from protein, 26% were from carbohydrate, and 69% were from fat. The fat load contained 453 mg of cholesterol and a polyunsaturated/ saturated fatty acid ratio of 0.06. The meal (69% fat, 1298 kcal/ 350 mL) volume was calculated per body surface area by using the following formula: volume = 350 3 body surface area/2, which has been used by our group previously (22) . The fat load was consumed within 10 minutes. Blood was drawn before and 2, 4, and 6 hours after the fat load. The 0-and 4-hour samples had their lipoprotein subfractions separated by cumulative floatation ultracentrifugation, and their cholesterol and TG contents were determined at each time point. Blood was collected into EDTA-Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ) and centrifuged at 3000 rpm for 10 minutes at 22°C to obtain plasma and leukocytes. To obtain serum for lipid measurements, blood was collected into serum separation tubes/ Vacutainer tubes, allowed to clot at room temperature for 20 minutes, and centrifuged at 3000 rpm for 10 minutes at 22°C.
ApoE genotyping
Genomic DNA was available for apoE exon sequencing from our previous study (21) . Primers used to encompass the ApoE2 and ApoE4 gene variations were forward 5 0 TAAGCTTGG-CACGGCTGTCCAAGGA3 0 and reverse 5 0 TAAGCTTGGC-ACGGCTGTCCAAGGA 3 0 (23). Fifty nanograms of genomic DNA was used in the polymerase chain reaction for amplification by using platinum Taq DNA polymerase (Invitrogen, Burlington, ON, Canada). Cycle conditions were denaturation for 2 minutes at 94°C, annealing for 2 minutes at 64°C, and extension for 3 minutes at 72°C with final extension of 5 minutes at 72°C for a total of 35 cycles. Amplified DNA were analyzed by standard DNA-sequencing reactions carried out as a service by BioBasic Sequencing (Markham, ON, Canada)
Measurement of serum lipid and lipoproteins
Fasting plasma apoB48, total apoB, apoCII, and apoCIII, as well as subsequent postprandial (2-, 4-, and 6-hour) measures of apoB48 and total apoB concentrations, were analyzed by using a highly sensitive chromogenic sandwich enzyme-linked immunosorbent assay (Shibayagi Co. Ltd., Japan; Alercheck Inc; and Abcam, respectively). All samples were quantified two times, and absorbance was measured spectrophotometrically with an intra-assay coefficient of variability (CV) of 4.8% to 5% and interassay CV of 7.5% to 9.7%. Serum PCSK9 was quantified by using a human PCSK9 enzyme-linked immunosorbent assay (CyClex Co., Japan). Serum PCSK9 was quantified four times with an intra-assay CV of 1.5% to 2.6% and an interassay CV of 2.9% to 7.1%.
Statistical analysis
GraphPad Prism 5 software (GraphPad Software Inc.) and SPSS software, version 20 (IBM, Chicago, IL), were used for statistical analysis. The data are presented as mean (standard deviation) or frequency and percentage. All continuous variables were tested for normal distribution by using the Shapiro-Wilk test; normally distributed data were analyzed by using the Student t test (unpaired and paired), and nonnormally distributed data were evaluated by using the Mann-Whitney U test for unpaired samples and Wilcoxon signed-rank test for paired samples. Categorical variables were tested by using x 2 or Fisher exact test. Area under the curve (AUC) was calculated through GraphPad Prism 5 software and corresponds to the total plasma concentration over the 6-hour postprandial measured. The fasting concentration of the respective parameter is further subtracted from the total AUC to generate the incremental AUC (iAUC). The iAUC represents the rate of change in the postprandial response adjusted for the initial concentration of the parameter. Outliers were identified by using the ROUT" Q = 1% method recommended in GraphPad Prism. Three outliers were removed from the TG AUC, and two outliers were removed from calculated apoB48 AUC by using this method. Differences in groups were established by using the Student t test, and a P value , 0.05 was considered to represent a statistically significant difference.
Results
Fasting biochemical profile of PCSK9-LOF variant participants
Anthropometry and fasting biochemistry of PCSK9-LOF variant participants and nonvariant control participants are summarized in Table 1 . The reduction in baseline TG is similar to that seen with other LOF variants (8, 9) . Participants were similar in age, sex, weight, height, BMI, waist circumference, and apoE genotype.
LOF variants had significantly reduced fasting LDL-C (213.6%), total cholesterol (27.1%), TG (221.3%), apoB48 (225.7%), and VLDL-C (234%). Additionally, LOF variants had nonsignificantly lower levels of total apoB (217.6%; P = 0.059) and PCSK9 (216.8%; P = 0.077) compared with those without variants. Fasting HDL-C (P = 0.46), apoCII (P = 0.13), and apoCIII (P = 0.66) did not significantly differ between the groups (Table 1) .
Postprandial response of TGs, ApoB, and PCSK9
The postprandial response and quantified AUC and iAUC of TG, apoB (total apoB and apoB48), and PCSK9 are shown in Fig. 1 . Carriers of PCSK9-LOF variants had reduced postprandial response in all parameters examined. The total apoB AUC was significantly lower for LOF variants (217%), whereas the iAUC was almost identical between groups. The TG AUC and iAUC were significantly lower for LOF variants than nonvariants (AUC LOF 218% AUC nonvariant; iAUC LOF 237% nonvariant). The apoB48 AUC and iAUC were significantly reduced for LOF variants (223% and 235%, respectively).
At 4 hours after fat load, PCSK9 values drastically declined in both LOF and nonvariant groups. Interestingly, the 4-hour postprandial decline was much greater for the LOF group than the nonvariant (224% vs 216%, respectively; P = 0.06).
Lipoprotein subfraction analysis
The TG and cholesterol concentrations in lipoprotein subfractions are shown in Fig. 2 . There was no difference in fasting and 4-hour postprandial TG and cholesterol levels in the CM fraction between PCSK9-LOF and nonvariant participants. However, the concentrations of non-CM TG and cholesterol at both time points were significantly lower in PCSK9-LOF participants than nonvariant individuals (Fig. 2) . Likewise, in the non-CM lipoprotein subfractions (VLDL1, VLDL2, intermediate-density lipoprotein, LDL1, and LDL2), the TG and cholesterol concentrations were mostly decreased in PCSK9-LOF participants at both time points, as shown in Fig. 2 . However, there was no apparent preferential enrichment or depletion of cholesterol or TG among lipoprotein subfractions between groups.
Discussion
PCSK9 LOF variants have reduced TRL
The major finding of this study is that humans with PCSK9-LOF variants have lower circulating TRL remnants than those with no PCSK9-LOF variants. The effect of circulating PCSK9 on LDL metabolism has been well established, but our findings demonstrate that PCSK9 also influences TRL metabolism. Specifically, we observed that individuals carrying LOF variants in PCSK9 have reduced circulating postprandial lipoproteins, which consist primarily of CM, VLDL, and their remnants. A second important finding in our study is the decline in circulating PCSK9 after an oral fat load. The postprandial decline in PCSK9 was observed in both LOF and nonvariant individuals. These novel findings add to the evidence for a role of PCSK9 in TRL metabolism (24) (25) (26) . Cholesterol-rich apoB-containing lipoproteins are known to be causally involved in atherogenesis (27) . We can consider that the reduction in CAD risk associated with PCSK9-LOF variants (8, 9) may be attributed to (5) . Thus, the magnitude of decrease in baseline TG level in our study (21%) is close to that seen in response to anti-PCSK9 therapy, which was associated with reduced risk for cardiovascular events (5) . This highlights the importance of a potential role of PCSK9 in TRL metabolism.
PCSK9 LOF variants are protected against postprandial lipemia
We demonstrated that PCSK9-LOF variants have lower TG and apoB48 not only during fasting but also during the fed or postprandial state. Elevated fasting apoB48 predicts fat intolerance (as measured by postprandial apoB48 and TG) (15) . The present findings Figure 1 . The postprandial response of plasma TG, apoB48, total apoB, and PCSK9 in PCSK9-LOF variant and nonvariant control participants. Participants were given a fat load to consume after a 12-hour fast. Blood was drawn before and 2, 4, and 6 hours after consumption. Data are shown as (a) the mean 6 standard deviation, (b) as AUC values (6 standard deviation), and (c) iAUC values (6 standard deviation). For nonvariant and PCSK9 LOF variant groups, respectively, n = 23 and 22 for total-apoB and PCSK9, n = 23 and 19 for TG data, and n = 23 and 20 for apoB48 data. *P , 0.05.
demonstrate that LOF variants are protected from fat intolerance. The mechanisms responsible for attenuation of PPL in our participants with PCSK9-LOF variants remain to be clarified. A possible mechanism is the wellknown association of diminished PCSK9 activity with an increase in the LDLR, which in addition to binding apoB can also bind apoE, resulting in greater clearance of apoE-containing CM remnants and VLDL remnants (7, 15, 28) . Another possibility is that PCSK9 may affect TRL clearance through its effects on other receptors in the LDLR family, including LRP1, VLDL receptor (VLDLR), and apoE receptor 2 (29, 30) . In particular, LRP1 has been shown in preclinical studies to be an important factor in the clearance of CM remnants and VLDLR. PCSK9 can mediate degradation of LRP-1, and LRP-1 competes with the LDLR for PCSK9 activity (30) . Although research has shown that PCSK9 induces degradation of VLDLR and apoE receptor 2, it is less clear whether these receptors play an important role in TRL clearance in humans (30) . Beyond an alteration in receptor-mediated TRL clearance, it is also possible that PCSK9 may affect the lipolysis of CM and VLDL and their remnants. To test this, we measured the fasting concentration of apoCII and CIII, which are apolipoproteins involved in the regulation of lipoprotein lipase. We did not find any differences in fasting apoCII, apoCIII, or CII/CIII ratio between groups, suggesting that alterations in lipolysis are a less likely mechanism for PCSK9's action on TRL clearance in this population.
Our non-CM and subfraction data indicate a reduction in fasting and postprandial lipoprotein remnants and LDL. TG and cholesterol concentrations were most strikingly reduced in the LDL2 subfraction, but least so in the LDL1 subfraction in the PCSK9-LOF variants. A reduction in the LDL2 subfraction is consistent with the well-recognized increase in LDLR associated with having PCSK9-LOF variants (31). PCSK9 is highly expressed in the intestine, where it possibly has a role in CM production and transintestinal cholesterol excretion (32) . In the current study, there were no differences between fasting and 4-hour postprandial CM-TG and cholesterol levels in PCSK9 LOF variant and nonvariant participants. Kinetic data are necessary to determine whether CM production rate is diminished in the presence of PCSK9-LOF variants.
The relationship between PPL and PCSK9 is not well studied. Le May et al. (20) showed an attenuated postprandial TG response to an oral olive oil load in PCSK9 knockout mice compared with their wild-type littermates, consistent with the findings of the current study. Conversely, Cariou et al. (33) demonstrated that an oral fat load in two heterozygous carriers of the R104C-V114A PCSK9-LOF mutation did not alter postprandial plasma TG concentrations compared with nonvariant participants. The authors concluded that plasma PCSK9 was not associated with PPL in humans. The discordance between our studies may be attributed to the phenotype of the variants studied. The LOF variants in Cariou and colleagues' study had very low to undetectable plasma PCSK9 and very low plasma LDL-C. In the current study, the PCSK9-LOF variants studied (L10ins/A53V and/or I474V and/or R46L) had modest lowering of circulating PCSK9 and lower but normal plasma LDL-C concentrations. Different PCSK9 variants appear to result in different biochemical characteristics (34, 35) and therefore may explain the differences between these two postprandial studies. Additionally, Chan and colleagues (36) conducted a postprandial study on 17 obese participants and demonstrated a positive association between plasma PCSK9 and the AUC and iAUC for apoB48 and an inverse association with TRL-apoB48 fractional clearance rate. In the current study, we similarly showed a reduction in fasting apoB48 and apoB48 AUC and iAUC. However, the study by Chan and colleagues was based on plasma PCSK9 concentration, whereas the current study is based on PCSK9 genotype. Plasma PCSK9 significantly declines following a high-fat meal Plasma PCSK9 was found to decline 4 hours after an acute oral fat load in individuals with and without LOF PCSK9 variants. Cariou et al. (33) studied two LOF PCSK9 participants and also observed significant decreases in serum postprandial PCSK9, consistent with our results. However, the authors further reported postprandial PCSK9 was unchanged after an acute fat load in 10 healthy volunteers (33) . The discrepancy in the postprandial response of plasma PCSK9 between studies is unclear but could be due to the composition of the meals given. A decrease in plasma PCSK9 after an acute oral fat load may be a result of PCSK9 expression being under the control of the nuclear transcription factors sterol response element binding protein (SREBP)-2 (37) and SREBP-1c (38) , both of which act through the same response element on the promotor of PCSK9 (38) . Increased postprandial cholesterol and fatty acids would reduce PCSK9 expression through a suppression of hepatic SREBP-2 and SREBP-1c, respectively. PCSK9-LOF variants could also lower circulating PCSK9 by reducing hepatic LDLR degradation (7) . Circulating PCSK9 is primarily cleared from the circulation by hepatic LDLR (39) . Therefore, increased LDLR expression in participants carrying LOF variants may enhance the clearance of circulating PCSK9, resulting in a more acute postprandial decline in PCSK9.
Strengths and limitations
This study examined fasting and postprandial lipoproteins from a subset of individuals with PCSK9-LOF variants from our Ottawa cohort (21) . The use of full exonic sequencing to identify well-defined variant and control populations was a major strength of the current study. This genotyping approach allowed us to ensure that variant participants had no other PCSK9 variants, and nonvariant control participants had no PCSK9 variants. The exclusion of participants carrying an apoE2 allele added to the robustness of our genotyping approach.
Additionally, our study participants had PCSK9 variants associated with a relatively small but significant LOF effect on LDL-C levels. No participant had LOF mutations Q152H (40), Y142X, and C679X (8, 9) , which are typically associated with major reductions in LDL-C levels. We speculate that any effects on fasting and postprandial concentrations of remnant lipoproteins seen with our "subtle" LOF variants may be even more pronounced with stronger LOF PCSK9 variants. None of our participants had a GOF variant. It is not known whether GOF variants are associated with enhanced PPL. We recognize that studying PPL in individuals with major LOF or GOF variants might provide information of greater clinical relevance, but these variants are uncommon. We chose LOF PCSK9 variants that are common in the Canadian population and have been shown to affect lipid metabolism significantly, even in the heterozygous state (21) . Thus, our results apply to a larger portion of the population than had the effects been shown in participants with rare but stronger LOF and/or GOF variants.
Because different LOF variants may have different effects on lipoprotein metabolism, it would be informative to compare the effects of different LOF variants. However, subgroup analysis was not possible in our study because the number of participants in the subgroups would be too small. Several participants were LOF compound heterozygotes, making the number of participants with a single LOF variant even smaller.
Conclusion
This study demonstrated that PCSK9-LOF variants are associated with attenuated fasting and postprandial response of plasma TG, apoB48, and total apoB. This may protect against CVD and further validate the use of PCSK9 inhibitors to lower CVD risk.
